SCHEMBL1179639

SCHEMBL1179639

CSC(=NS(=O)(=O)c1ccc(N)cc1)SC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.71
LMNA P02545 4/20 0.68
ALDH1A1 P00352 3/20 0.68
MAPT P10636 2/20 0.68
KDM4E B2RXH2 1/20 0.68
F2 P00734 8/20 0.61
PRSS1 P07477 8/20 0.61
PRSS2 P07478 8/20 0.61
PRSS3 P35030 8/20 0.61
AGO2 Q9UKV8 2/20 0.61
PKM P14618 1/20 0.46
TSHR P16473 3/20 0.45
NT5E P21589 1/20 0.45
KMT2A Q03164 1/20 0.45
MPO P05164 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HTR6 P50406 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14753500 0.89 HTT (0.57) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL1564086 0.83 HTT (1.00) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL30630025 0.81 HTT (0.71) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL3922906 0.81 HTT (0.71) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL3618541 0.81 MAPT (1.00) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL12886466 0.79 HTT (0.67) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL1178744 0.79 HTT (0.67) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL26546139 0.77 HTT (0.65) HTTLMNAALDH1A1MAPTKDM4E
SCHEMBL1178963 0.77 HTT (0.55) HTTLMNAALDH1A1MAPTKDM4E
Sulfaguanidine SCHEMBL1650003 0.76 F2 (1.00) LMNAALDH1A1F2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2610247-B1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LTD (BS) 2016-05-25 EP disclosed
EP-2610247-B1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LTD (BS) 2016-05-25 EP disclosed
EP-2265589-B1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LTD (BS) 2016-01-27 EP disclosed
EP-2265589-B1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LTD (BS) 2016-01-27 EP disclosed
US-9126942-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2015-09-08 US disclosed
US-9126942-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2015-09-08 US disclosed
US-9126942-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2015-09-08 US disclosed
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LIMITED (BS) 2015-02-19 US disclosed
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LIMITED (BS) 2015-02-19 US disclosed
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LIMITED (BS) 2015-02-19 US disclosed
EP-2610247-A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbott Healthcare Products B.V. (NL) 2013-07-03 EP disclosed
EP-2610247-A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbott Healthcare Products B.V. (NL) 2013-07-03 EP disclosed
WO-2011092226-A1 SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2011-08-04 WO disclosed
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HOSPITALS LIMITED (BS) 2011-02-24 US disclosed
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HOSPITALS LIMITED (BS) 2011-02-24 US disclosed
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HOSPITALS LIMITED (BS) 2011-02-24 US disclosed
EP-2265589-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS Abbott Healthcare Products B.V. (NL) 2010-12-29 EP disclosed
WO-2009115515-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2009-09-24 WO disclosed
WO-2009115515-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2009-09-24 WO disclosed
US-4379784-A ANTIBIOTICS DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 HTT 36/4885LMNA 4603/4885ALDH1A1 2125/4885
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 HTT 36/4885LMNA 4603/4885ALDH1A1 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.